|
Source - MediLexicon – Abbott has announced that it has received marketing authorisation from the European Commission for the tablet formulation of Kaletra(R) (lopinavir/ritonavir), a new, more convenient version of the leading protease inhibitor (PI) prescribed worldwide for the treatment of HIV. The new formulation does not require refrigeration and will reduce the number of tablets required to achieve the recommended daily dose, when compared with the soft capsules.
For more information go to: http://www.pharma-lexicon.com/medicalnews.php?newsid=46463
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 4th July 2006
|
